Home - Clinical Trials Arena
WEBAstraZeneca eyes up transition to eco-friendly inhaler propellant. Results from AstraZeneca’s completed clinical studies will be shared with regulatory authorities by the end of this year. More themes. Artificial Intelligence.
Gilead’s lenacapavir: HIV prospects strongest in long-acting …
WEBAug 25, 2021 · Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said. Manasi Vaidya August 25, 2021. Gilead announced a collaboration with Merck in March to study lenacapavir with islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), which is also a new drug class in HIV.
Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA
WEBJun 19, 2024 · Mounjaro ™ (tirzepatide) is a dual-targeted, injectable, sustained-release therapy indicated for the treatment of type 2 diabetes (T2D) in adults as an adjunct to diet and exercise.. Developed by Eli Lilly, a pharmaceutical company based in the US, Mounjaro is the first and only once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor ...
Phase 0 clinical trials: what you need to know
WEBJul 21, 2022 · Clinical Trials Arena breaks down the two most common types of Phase 0 trials, including window of opportunity trials in neuro-oncology. William Newton July 21, 2022. When the FDA introduced Phase 0 trials in 2006, the goal was to learn more about new drugs without exposing subjects to their full, potentially toxic, effects.
A closer look at Regeneron and its efforts to provide Covid-19 …
WEBJun 19, 2020 · Having grown into one of the biggest companies in the biotech sphere since its inception in 1988, Regeneron is now working to develop a Covid-19 treatment. Regeneron is testing sarilumab – an existing rheumatoid arthritis drug – in Covid-19 patients (Credit: Regeneron/Sanofi) Like many firms in the pharmaceutical sector, Regeneron has ...
Care Access Research and AstraZeneca partner for Covid-19 trial
WEBJan 27, 2021 · Decentralised research organisation (DRO) Care Access Research has collaborated with AstraZeneca to speed up the Phase III STORM CHASER clinical trial in the US assessing the latter’s long-acting monoclonal antibody (LAAB) combination, AZD7442, for preventing Covid-19. Vishnu Priyan January 27, 2021. The trial will have individuals living or ...
Hidradenitis Suppurativa Ripe for competition with Humira
WEBJul 29, 2021 · Analysts forecast that the global hidradenitis suppurativa market may garner sales of $763.6m in 2021, with a compound annual growth rate of 4.2% up to 2023. Moderate-to-severe patients have varying efficacy milage with Humira, underscoring the need for more biologic options. Candidates Cosentyx and bimekizumab are possible contenders with ...
CanSino’s shot shows 96% efficacy against severe Covid-19 in trial
WEBDec 27, 2021 · CanSino Biologics (CanSinoBIO) has reported that its recombinant Covid-19 vaccine, Convidecia, demonstrated 96% efficacy in averting severe disease in Phase III clinical trial. The international, randomised, double-blind, multicentre and placebo-controlled trial enrolled 45,000 adult subjects aged 18 years and above in Argentina, Chile, Mexico ...
Argenica Therapeutics greenlit to launch Phase II trials into stroke ...
WEBOct 4, 2023 · The Australian-based biotechnology company Argenica has been given the go-ahead to enter Phase II clinical trials of ARG-007 for the treatment of acute ischaemic stroke (AIS) patients. Argenica Therapeutics received the nod from St Vincent’s Hospital Melbourne’s Human Research Ethics Committee (HREC), with the first patients set to begin ...
Novo Nordisk launches trial of pipeline drug CagriSema versus …
WEBNov 17, 2023 · Novo Nordisk launches trial of pipeline drug CagriSema versus newly approved Zepbound. The launch of this Phase III comparative trial by Novo Nordisk might imply that CagriSema and Zepbound are expected to become direct competitors once Novo Nordisk’s candidate reaches the market.